MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/po.22.00390

Медицинская библиотека · JCO precision oncology · 2022

Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer.

Lazo De La Vega Lorena, Comeau Hannah, Sallan Sarah, Al-Ibraheemi Alyaa, Gupta Hersh, Li Yvonne Y, Tsai Harrison K, Kang Wenjun, Ward Abigail, Church Alanna J, Kim AeRang, Pinto Navin R, Macy Margaret E, Maese Luke D, Sabnis Amit J, Cherniack Andrew D, Lindeman Neal I, Anderson Megan E, Cooney Tabitha M, Yeo Kee Kiat, Reaman Gregory H, DuBois Steven G, Collins Natalie B, Johnson Bruce E, Janeway Katherine A, Forrest Suzanne J

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Multiple FGFR inhibitors are currently in clinical trials enrolling adults with different solid tumors, while very few enroll pediatric patients. We determined the types and frequency of FGFR alterations (FGFR1-4) in pediatric cancers to inform future clinical trial design.

METHODS

Tumors with FGFR alterations were identified from two large cohorts of pediatric solid tumors subjected to targeted DNA sequencing: The Dana-Farber/Boston Children's Profile Study (n = 888) and the multi-institution GAIN/iCAT2 (Genomic Assessment Improves Novel Therapy) Study (n = 571). Data from the combined patient population of 1,395 cases (64 patients were enrolled in both studies) were reviewed and cases in which an FGFR alteration was identified by OncoPanel sequencing were further assessed.

RESULTS

We identified 41 patients with tumors harboring an oncogenic FGFR alteration. Median age at diagnosis was 8 years (range, 6 months-26 years). Diagnoses included 11 rhabdomyosarcomas, nine low-grade gliomas, and 17 other tumor types. Alterations included gain-of-function sequence variants (n = 19), amplifications (n = 10), oncogenic fusions (FGFR3::TACC3 [n = 3], FGFR1::TACC1 [n = 1], FGFR1::EBF2 [n = 1], FGFR1::CLIP2 [n = 1], and FGFR2::CTNNA3 [n = 1]), pathogenic-leaning variants of uncertain significance (n = 4), and amplification in combination with a pathogenic-leaning variant of uncertain significance (n = 1). Two novel FGFR1 fusions in two different patients were identified in this cohort, one of whom showed a response to an FGFR inhibitor.

CONCLUSION

In summary, activating FGFR alterations were found in approximately 3% (41/1,395) of pediatric solid tumors, identifying a population of children with cancer who may be eligible and good candidates for trials evaluating FGFR-targeted therapy. Importantly, the genomic and clinical data from this study can help inform drug development in accordance with the Research to Accelerate Cures and Equity for Children Act.

Для цитирования: Lazo De La Vega Lorena, Comeau Hannah, Sallan Sarah, Al-Ibraheemi Alyaa, Gupta Hersh, Li Yvonne Y, Tsai Harrison K, Kang Wenjun, Ward Abigail, Church Alanna J, Kim AeRang, Pinto Navin R, Macy Margaret E, Maese Luke D, Sabnis Amit J, Cherniack Andrew D, Lindeman Neal I, Anderson Megan E, Cooney Tabitha M, Yeo Kee Kiat, Reaman Gregory H, DuBois Steven G, Collins Natalie B, Johnson Bruce E, Janeway Katherine A, Forrest Suzanne J. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer.. JCO precision oncology. 2022. DOI: 10.1200/po.22.00390.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.